Colorectal Cancer Debate: First Line BRAF V600E - FOLFOXIRI/Bev

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab as 1L treatment of BRAF V600E-mutant mCRCПодробнее

Debate 1: First-line Treatment of Metastatic Colorectal Cancer - FIRE-3Подробнее

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of...Подробнее

BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRCПодробнее

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Подробнее

Debate: First line EGFR therapy for left sided RAS/BRAF WT metastatic colon cancer? - YesПодробнее

First-Line Triplet in BRAF+ mCRCПодробнее

Colorectal Cancer Debate: First Line BRAF V600E - Targeted TripletПодробнее

Debate 2: BRAF mutant mCRC patients - FOLFIRINOX/BevПодробнее

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Bevacizumab or EGFR antibodiesПодробнее

Case 1: BRAF-Mutated Metastatic Colorectal CancerПодробнее

Debate: Borderline resectable liver metastasis in RAS WT CRC? - FOLFOX (or FOLFOXIRI)/BevПодробнее

Dr. Cremolini on FOLFOXIRI Plus Bevacizumab For Metastatic Colorectal CancerПодробнее

Encorafenib & Binimetinib + Cetuximab for Untreated BRAF V600E-Mutant Metastatic Colorectal CancerПодробнее

Debate: MSI High Colon Cancer - ImmunotherapyПодробнее

Debate 1: First-line Treatment of Metastatic Colorectal Cancer - CALGB 80405Подробнее

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRCПодробнее

Debate: MSI High Colon Cancer - Upfront ChemotherapyПодробнее

Debate 2: BRAF Mutant mCRC Patients - Clinical TrialПодробнее